Home/Pipeline/Novilase for Malignant Breast Tumors (EU)

Novilase for Malignant Breast Tumors (EU)

Focal destruction of malignant breast tumors

CommercialActive

Key Facts

Indication
Focal destruction of malignant breast tumors
Phase
Commercial
Status
Active
Company

About Novian Health

Novian Health is a medical device innovator developing the Novilase Interstitial Laser System for the thermal ablation of tumors, with a primary focus on breast cancer and benign breast tumors. The technology has achieved CE Mark approval in Europe for both malignant and benign indications and holds FDA 510(k) clearance in the U.S. for benign tumors and soft tissue ablation, with Breakthrough Device designation for malignant breast tumors. The company is preparing for a pivotal U.S. trial (BR-003) to support FDA marketing clearance for the malignant indication while building commercial and clinical evidence through post-market registries.

View full company profile

Therapeutic Areas

Other Focal destruction of malignant breast tumors Drugs

DrugCompanyPhase
Novilase for Malignant Breast Tumors (U.S.)Novian HealthPivotal Trial